Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 1

Tests universal CAR T cells in people with multiple myeloma in remission

Tests universal CAR T immune cells in adults with multiple myeloma in remission.

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
Shenzhen, ChinaSee the site
Trial code
Registry title
Universal CAR-T Cells Targeting Multiple Myeloma
Status
Not yet recruiting
Phase
Phase 1
People taking part
20 people, planned
Starts
30 Jun 2027
Expected to end
31 Dec 2028
Type of study
Interventional
Treatments tested
  • MM-specific universal CAR T cells
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 80 with multiple myeloma that did not respond to earlier treatment, or came back after it.

Age
18 to 80 years
Sex
All sexes can join.
Disease stage
Confirmed multiple myeloma. Remission could not be reached after at least 2 earlier treatment regimens, or the disease came back after a stem cell transplant, or high-risk myeloma in first or second remission that cannot have a transplant because of age or other illness.
Earlier treatment
Earlier treatments failed, including stem cell transplant for some people. Previous related CAR-T cell therapy is not allowed.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Uncontrolled active infection
  • Active hepatitis B or hepatitis C infection
  • HIV infection
  • Current use of systemic steroids

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients with confirmed multiple myeloma failed curative treatment options (including autologous or allogeneic SCT)
  • Complete remission (CR) cannot be achieved after at least 2 prior therapy regimens
  • High risk MM in CR1 or CR2 and not eligible for SCT because of age or comorbid diseases
  • Less than 1 year between last chemotherapy and progression (i.e. most recent progression free interval < 1 year)
  • Relapsed after prior autologous or allogenic SCT with residual disease after at least 1 prior therapy and not eligible for allogeneic SCT
  • Residual disease after primary therapy and not eligible for ASCT
  • Expected survival > 12 weeks• Creatinine < 2.5 mg/dl• ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 3x normal
  • Bilirubin < 2.0 mg/dl
  • Any relapse after prior SCT is eligible regardless of other prior therapy
  • Adequate venous access for apheresis, and no other contraindications for leukapheresis
  • Voluntary informed consent is signed

Who cannot take part

  • Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary
  • Previous related CAR-T cell therapy
  • Uncontrolled active infection
  • Active hepatitis B or hepatitis C infection
  • Any uncontrolled active medical disorder that would preclude participation
  • HIV infection
  • Pregnant or lactating women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in China

  • Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, PhDNo longer taking part

About the trial

What the trial wants to find out

The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.

The group in the trial

  • Universal CART cells to treat MMTreatment being tested

    Treatment: MM-specific universal CAR T cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Universal CAR-T Cells for the Treatment of Multiple Myeloma
Plain-language title
Tests universal CAR T cells in people with multiple myeloma in remissionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06006741, who can take part
Record updated
2 November 2026